Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on January 1, 2026, the Company granted (i) non-qualified stock options to one newly-hired non-executive employee to purchase a total of 48,000 shares of the Company's common stock at an exercise price per share of $0.98, which was the closing price per share of the Company's common stock as reported by NASDAQ on December 31, 2025, and (ii) restricted stock units (RSUs) representing 79,400 shares of its common stock to four newly-hired non-executive employees, including the newly-hired employee receiving the non-qualified stock options referenced above. The grants were approved by the Compensation Committee of the Company's Board of Directors and granted under the Company's Amended and Restated Inducement Equity Plan as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The options will vest over four years, with 25% of the shares underlying the option vesting on the one-year anniversary of the grant date and the remaining 75% vesting in approximately equal monthly installments over the following thirty-six months, subject to the employee being continuously employed by the Company through each vesting date. The RSUs will vest over four years, with 25% of the shares underlying each RSU award vesting on each anniversary of the grant date, subject to the employees being continuously employed by the Company through each vesting date.

GlobeNewsWire • Jan 5, 2026

Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference

SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that the Company will present at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025 in New York, New York. Company management will participate in a fireside chat at 9:00 AM ET and a cell therapy panel discussion at 12:00 PM ET.

GlobeNewsWire • Nov 25, 2025

Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates

Authorization Received from UK and EU Authorities to Activate ex-US Clinical Trial Sites Supporting the Ongoing Patient Enrollment of FT819, an Off-the-Shelf CD19-targeted CAR T-cell Product Candidate that Utilizes Less-intensive or No Conditioning, Enabling Broad Patient Accessibility

GlobeNewsWire • Nov 13, 2025

Fate Therapeutics (FATE) Reports Q3 Loss, Beats Revenue Estimates

Fate Therapeutics (FATE) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.4 per share a year ago.

Zacks Investment Research • Nov 13, 2025

Fate Therapeutics (FATE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Fate Therapeutics (FATE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Nov 4, 2025

3 Cancer-Focused Stocks Showing Strong Pipeline Progress

Relay, Fate and Verastem advance promising cancer therapies, strengthening their pipelines in a rapidly evolving oncology market.

Zacks Investment Research • Oct 28, 2025

Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy

As of a September 25, 2025 data cut-off-date, 10 patients with treatment-refractory, moderate-to-severe Systemic Lupus Erythematosus (SLE) were treated with a single dose of FT819 with less-intensive or no conditioning chemotherapy

GlobeNewsWire • Oct 26, 2025

Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates

First patient treated with FT819 off-the-shelf CAR T-cell product candidate following fludarabine-free conditioning for severe lupus nephritis demonstrated durability of response with drug-free definition of remission in systemic lupus erythematosus (DORIS) at 12-month follow-up

GlobeNewsWire • Aug 12, 2025

Fate Therapeutics (FATE) Reports Q2 Loss, Beats Revenue Estimates

Fate Therapeutics (FATE) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to a loss of $0.33 per share a year ago.

Zacks Investment Research • Aug 12, 2025

Why Is Fate Therapeutics (FATE) Up 61.5% Since Last Earnings Report?

Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Jun 12, 2025